The ongoing search for translationally relevant preclinical pulmonary fibrosis models
Idiopathic Pulmonary Fibrosis (IPF) is a chronic and irreversible respiratory disease, characterized by the build-up of scar tissue in the lungs. The excessive formation of this collagen-based material results in severe breathing difficulties and is ultimately fatal. As the onset of symptoms is gradual, IPF is difficult to detect in the early stages of its development. However, once established, patient prognosis is poor, with average post-diagnosis survival times of just three years.
A significant amount of resource has been invested in the search for potential IPF treatments. While a large number of molecules have shown promise in preclinical assays and animal models, when it comes to translating this activity into effective treatments, development efforts have met with limited success.
Download your copy of this educational article from Vince Russell, Director Respiratory, Medicinal Chemistry today and discover more.